Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVD-003 for Recalcitrant Lower Limb Nonunion
2024-517762-42-01Phase 2Authorised
- Sponsor
- Novadip Biosciences
- Start
- Jan 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of NVD-003 in Nonunion of Lower Limb Long Bone Fracture, sponsored by Novadip Biosciences. Primary endpoints: Overall safety from graft implantation until completion of visit V7 and General safety parameters at scheduled visits. Planned start Jan 2025; status: authorised.
02
Drugs
NVD-003
03
Conditions
Nonunion of Lower Limb Long Bone Fracture
Beyond the preview
Go deeper on 2024-517762-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517762-42-01.